The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1523
ISSUE1523
June 19, 2017
Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
June 19, 2017 (Issue: 1523)
The FDA has approved abaloparatide (Tymlos –
Radius Health), a synthetic analog of human
parathyroid hormone related peptide, for treatment
of postmenopausal women with osteoporosis who
are at high risk for fracture. Abaloparatide is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.